Neurocrine Biosciences has posted results from the Phase IIb Kinect 2 study of NBI-98854, a small molecule VMAT2 inhibitor. The company reports that it showed a statistically significant and clinically meaningful reduction in tardive dyskinesia symptoms. The pre-specified primary endpoint was the change-from-baseline in the Abnormal Involuntary Movement Scale (AIMS) at Week 6 as assessed by central blinded video raters. The improvement in Week 6 AIMS was also corroborated by the Clinical Global...